![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/1/1d/Sitagliptin.svg/640px-Sitagliptin.svg.png&w=640&q=50)
Sitagliptin
Diabetes medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about sitagliptin?
Summarize this article for a 10 year old
Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes.[7] In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea.[8] It is taken by mouth.[7] It is also available in the fixed-dose combination medication sitagliptin/metformin (Janumet, Janumet XR).[7]
![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /sɪtəˈɡlɪptɪn/ ⓘ |
Trade names | Januvia, Zituvio, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606023 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 87% |
Protein binding | 38% |
Metabolism | Liver (CYP3A4- and CYP2C8-mediated) |
Elimination half-life | 8 to 14 h[6] |
Excretion | Kidney (80%)[6] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.217.948 ![]() |
Chemical and physical data | |
Formula | C16H15F6N5O |
Molar mass | 407.320 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Common side effects include headaches, swelling of the legs, and upper respiratory tract infections.[7] Serious side effects may include angioedema, low blood sugar, kidney problems, pancreatitis, and joint pain.[7] Whether use in pregnancy or breastfeeding is safe is unclear.[9] It is in the dipeptidyl peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.[7]
Sitagliptin was developed by Merck & Co. and approved for medical use in the United States in 2006.[7] In 2021, it was the 83rd most commonly prescribed medication in the United States, with more than 8 million prescriptions.[10][11] It is available as a generic medication in Canada but not the United States.[12][13]